Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Helena A Yu, MD
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
47 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Odense C, Denmark
- Research Site
Catania, Italy
- Research Site
Naples, Italy
- Research Site
Orbassano, Italy
- Research Site
Padova, Italy
- Research Site
Varese, Italy
- Research Site
Chūōku, Japan
- Research Site
Fukuoka, Japan
- Research Site
Kōtoku, Japan
- Research Site
Nagoya, Japan
- Research Site
Osaka, Japan
- Research Site
Wakayama, Japan
- Research Site
Amsterdam, Netherlands
- Research Site
Amsterdam, Netherlands
- Research Site
Maastricht, Netherlands
- Research Site
Nijmegen, Netherlands
- Research Site
Rotterdam, Netherlands
- Research Site
Drammen, Norway
- Research Site
Oslo, Norway
- Research Site
Trondheim, Norway
- Research Site
Seongnam-si, South Korea
- Research Site
Seoul, South Korea
- Research Site
Seoul, South Korea
- Research Site
Seoul, South Korea
- Research Site
A Coruña, Spain
- Research Site
Barcelona, Spain
- Research Site
Barcelona, Spain
- Research Site
Madrid, Spain
- Research Site
Madrid, Spain
- Research Site
Seville, Spain
- Research Site
Stockholm, Sweden
- Research Site
Duarte, California, United States
- Research Site
Los Angeles, California, United States
- Research Site
Sacramento, California, United States
- Research Site
Santa Monica, California, United States
- Research Site
New Haven, Connecticut, United States
- Research Site
Chicago, Illinois, United States
- Research Site
Baltimore, Maryland, United States
- Research Site
Boston, Massachusetts, United States
- Research Site
Boston, Massachusetts, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 25 Jun 2019
- Primary completion
- 6 May 2025
- Completion
- 6 May 2025
- Last update posted
- 30 Jan 2025
- Registered enrollment
- 247
- Registry id
- NCT03944772
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.